Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies

2020 ◽  
Vol 10 (5) ◽  
pp. 324-329 ◽  
Author(s):  
Vivek Verma ◽  
Ethan B. Ludmir ◽  
Shane M. Mesko ◽  
Eric D. Brooks ◽  
Alexander Augustyn ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Radiation Oncology ◽  
Insurance Coverage ◽  
Commercial Insurance ◽  
American Society

scholarly journals Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline

2018 ◽  
Vol 8 (3) ◽  
pp. 145-152 ◽  
Author(s):  
Benjamin D. Smith ◽  
Jennifer R. Bellon ◽  
Rachel Blitzblau ◽  
Gary Freedman ◽  
Bruce Haffty ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Radiation Oncology ◽  
Evidence Based ◽  
Executive Summary ◽  
American Society ◽  
Evidence Based Guideline

scholarly journals Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

2020 ◽  
Vol 38 (18) ◽  
pp. 2080-2106 ◽  
Author(s):  
Nadine M. Tung ◽  
Judy C. Boughey ◽  
Lori J. Pierce ◽  
Mark E. Robson ◽  
Isabelle Bedrosian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Clinical Oncology ◽  
Radiation Oncology ◽  
Single Agent ◽  
Significant Risk ◽  
Surgical Oncology ◽  
Bilateral Mastectomy ◽  
Eligibility Criteria ◽  
American Society

PURPOSE To develop recommendations for management of patients with breast cancer (BC) with germline mutations in BC susceptibility genes. METHODS The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. RESULTS Fifty-eight articles met eligibility criteria and formed the evidentiary basis for the local therapy recommendations; six randomized controlled trials of systemic therapy met eligibility criteria. RECOMMENDATIONS Patients with newly diagnosed BC and BRCA1/ 2 mutations may be considered for breast-conserving therapy (BCT), with local control of the index cancer similar to that of noncarriers. The significant risk of a contralateral BC (CBC), especially in young women, and the higher risk of new cancers in the ipsilateral breast warrant discussion of bilateral mastectomy. Patients with mutations in moderate-risk genes should be offered BCT. For women with mutations in BRCA1/ 2 or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach. There is no evidence of increased toxicity or CBC events from radiation exposure in BRCA1/ 2 carriers. Radiation therapy should not be withheld in ATM carriers. For patients with germline TP53 mutations, mastectomy is advised; radiation therapy is contraindicated except in those with significant risk of locoregional recurrence. Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers. In the adjuvant/neoadjuvant setting, data do not support the routine addition of platinum to anthracycline- and taxane-based chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/ 2 carriers. Data are insufficient to recommend PARP inhibitor use in the early setting or in moderate-penetrance carriers. Additional information available at www.asco.org/breast-cancer-guidelines .

Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline

2015 ◽  
Vol 33 (26) ◽  
pp. 2908-2913 ◽  
Author(s):  
Larissa A. Meyer ◽  
Kari Bohlke ◽  
Matthew A. Powell ◽  
Amanda N. Fader ◽  
Gregg E. Franklin ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Radiation Oncology ◽  
Myometrial Invasion ◽  
Adjuvant Radiation ◽  
Postoperative Radiation Therapy ◽  
Grade 3 ◽  
American Society ◽  
Evidence Based Guideline

Purpose To provide guidance on the role of adjuvant radiation therapy in the treatment of endometrial cancer. Methods “The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline” by Klopp et al, published in 2014 in Practical Radiation Oncology, was reviewed for developmental rigor by methodologists. The American Society for Radiation Oncology (ASTRO) guideline content and recommendations were further reviewed by the American Society of Clinical Oncology (ASCO) Endorsement Panel. Results The ASCO Endorsement Panel determined that the recommendations from the ASTRO guideline are clear, thorough, and based on the most relevant scientific evidence. ASCO endorsed the ASTRO guideline with several qualifying statements. Recommendations Surveillance without adjuvant radiation therapy is a reasonable option for women without residual disease in the hysterectomy specimen and for women with grade 1 or 2 cancer and < 50% myometrial invasion, especially when no other high-risk features are present. For women with grade 1 or 2 cancer and ≥ 50% myometrial invasion or grade 3 cancer and < 50% myometrial invasion, vaginal brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence and is preferred. Patients with grade 3 cancer and ≥ 50% myometrial invasion or cervical stroma invasion may benefit from pelvic radiation to prevent pelvic recurrence. For women with high-risk early-stage disease and advanced disease, the ASCO Endorsement Panel added qualifying statements to the ASTRO recommendations to provide stronger statements in favor of chemotherapy (with or without radiation therapy).

Sign in / Sign up

Export Citation Format

Share Document